Thomas DesChamps
Directeur/Membre du Conseil chez Blue Ash Therapeutics LLC
Profil
Thomas DesChamps is currently a Director at Blue Ash Therapeutics LLC.
He was previously a Managing Director & Portfolio Manager at Healthcare Value Capital LLC and a Research Associate at Bear, Stearns & Co., Inc. He also worked as an Analyst at Bear Stearns Asset Management, Inc. from 2007 to 2008.
Mr. DesChamps received his undergraduate degree from Bucknell University in 1994 and his MBA from The Leonard N Stern School of Business in 2001.
Postes actifs de Thomas DesChamps
| Sociétés | Poste | Début |
|---|---|---|
Blue Ash Therapeutics LLC
 Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | Directeur/Membre du Conseil | - |
Anciens postes connus de Thomas DesChamps
| Sociétés | Poste | Fin |
|---|---|---|
Healthcare Value Capital LLC
 Healthcare Value Capital LLC Investment ManagersFinance Healthcare Value Capital LLC (HVC) is an independent hedge fund manager headquartered in Woodcliff Lake, New Jersey. The firm was founded by Joseph P. Riccardo in 2008. HVC manages healthcare focused investment funds for high net worth investors. | Gestionnaire de Portefeuille-Actions | 01/08/2022 |
Bear Stearns Asset Management, Inc.
 Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management Inc (Bear Stearns) is a Private Equity/Venture Capital firm, a subsidiary of The Bear Stearns Cos LLC founded in 1985. The firm is headquartered in the US. | Corporate Officer/Principal | 02/06/2008 |
Bear, Stearns & Co., Inc.
 Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information. | Analyst-Equity | 30/07/2007 |
Formation de Thomas DesChamps
| Bucknell University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Bear, Stearns & Co., Inc.
Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information. | Finance |
Bear Stearns Asset Management, Inc.
Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management Inc (Bear Stearns) is a Private Equity/Venture Capital firm, a subsidiary of The Bear Stearns Cos LLC founded in 1985. The firm is headquartered in the US. | Finance |
Healthcare Value Capital LLC
Healthcare Value Capital LLC Investment ManagersFinance Healthcare Value Capital LLC (HVC) is an independent hedge fund manager headquartered in Woodcliff Lake, New Jersey. The firm was founded by Joseph P. Riccardo in 2008. HVC manages healthcare focused investment funds for high net worth investors. | Finance |
Blue Ash Therapeutics LLC
Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | Health Technology |
